Univariate analyses of prognostic factors for an association with engraftment (log-rank test) and the risk of infection (Fisher exact test)
. | Days to ANC, > 500/μL . | . | . | Days to PLT, > 20 000/μL . | . | . | Documented infection . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | OR . | 95% CI . | P . | ||||||
| Older than 53 years | 0.66 | 0.36-1.21 | .18 | 0.90 | 0.53-1.53 | .71 | 2.30 | 0.78-6.98 | .14 | ||||||
| Female | 1.41 | 0.75-2.65 | .30 | 1.19 | 0.69-2.03 | .53 | 0.69 | 0.22-2.06 | .62 | ||||||
| Prior radiation | 0.70 | 0.37-1.33 | .28 | 0.76 | 0.44-1.31 | .31 | 1.04 | 0.33-3.14 | .99 | ||||||
| More than 6 chemotherapy cycles | 0.64 | 0.34-1.19 | .15 | 0.92 | 0.54-1.57 | .76 | 2.54 | 0.86-7.61 | .081 | ||||||
| At least 1 month of alkylating therapy | 0.58 | 0.31-1.08 | .091 | 0.69 | 0.40-1.19 | .19 | 1.22 | 0.42-3.61 | .81 | ||||||
| No. of leukaphereses higher than 2 | 0.32 | 0.17-0.61 | .001 | 0.64 | 0.37-1.09 | .11 | 1.46 | 0.50-4.41 | .47 | ||||||
| Second transplantation | 0.93 | 0.50-1.72 | .81 | 0.93 | 0.55-1.60 | .80 | 1.85 | 0.63-5.44 | .23 | ||||||
| At least 4000 WBCs before G-CSF | 1.53 | 0.83-2.82 | .17 | 1.30 | 0.77-2.20 | .32 | 0.66 | 0.23-1.94 | .47 | ||||||
| G-CSF response greater than median | 2.81 | 1.50-5.26 | .0016 | 3.07 | 1.74-5.42 | .0003 | 0.19 | 0.05-0.63 | .0030 | ||||||
| CD34+ cells greater than 4.0 × 106/kg | 8.18 | 4.11-16.2 | < .0001 | 2.47 | 1.41-4.33 | .0029 | 0.64 | 0.21-1.88 | .47 | ||||||
| Neutrophil count less than 500/μL for no more than 5 days | NA | NA | NA | NA | NA | NA | 0.26 | 0.08-0.80 | .011 | ||||||
. | Days to ANC, > 500/μL . | . | . | Days to PLT, > 20 000/μL . | . | . | Documented infection . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | OR . | 95% CI . | P . | ||||||
| Older than 53 years | 0.66 | 0.36-1.21 | .18 | 0.90 | 0.53-1.53 | .71 | 2.30 | 0.78-6.98 | .14 | ||||||
| Female | 1.41 | 0.75-2.65 | .30 | 1.19 | 0.69-2.03 | .53 | 0.69 | 0.22-2.06 | .62 | ||||||
| Prior radiation | 0.70 | 0.37-1.33 | .28 | 0.76 | 0.44-1.31 | .31 | 1.04 | 0.33-3.14 | .99 | ||||||
| More than 6 chemotherapy cycles | 0.64 | 0.34-1.19 | .15 | 0.92 | 0.54-1.57 | .76 | 2.54 | 0.86-7.61 | .081 | ||||||
| At least 1 month of alkylating therapy | 0.58 | 0.31-1.08 | .091 | 0.69 | 0.40-1.19 | .19 | 1.22 | 0.42-3.61 | .81 | ||||||
| No. of leukaphereses higher than 2 | 0.32 | 0.17-0.61 | .001 | 0.64 | 0.37-1.09 | .11 | 1.46 | 0.50-4.41 | .47 | ||||||
| Second transplantation | 0.93 | 0.50-1.72 | .81 | 0.93 | 0.55-1.60 | .80 | 1.85 | 0.63-5.44 | .23 | ||||||
| At least 4000 WBCs before G-CSF | 1.53 | 0.83-2.82 | .17 | 1.30 | 0.77-2.20 | .32 | 0.66 | 0.23-1.94 | .47 | ||||||
| G-CSF response greater than median | 2.81 | 1.50-5.26 | .0016 | 3.07 | 1.74-5.42 | .0003 | 0.19 | 0.05-0.63 | .0030 | ||||||
| CD34+ cells greater than 4.0 × 106/kg | 8.18 | 4.11-16.2 | < .0001 | 2.47 | 1.41-4.33 | .0029 | 0.64 | 0.21-1.88 | .47 | ||||||
| Neutrophil count less than 500/μL for no more than 5 days | NA | NA | NA | NA | NA | NA | 0.26 | 0.08-0.80 | .011 | ||||||
ANC indicates absolute neutrophil count; PLT, platelets; HR, hazard ratio; OR, odds ratio; and NA, not applicable.